Wockhardt gets FDA nod for generic DacogenDecitabine had an annual market value of $120 million, according to February 2019 IQVIA data. ANI Pharmaceuticals deal boosts injectable portfolioANI Pharmaceuticals has added a second specialty injectable product to its pipeline, the first product being Cortrophin gel. Teva launches generic AndroGel Testosterone gel 1.62% had an annual market value of more than $911 million, according to February 2019 IQVIA data. Lupin gets FDA green light for generic Prozac Fluoxetine tablets had an annual market value of roughly $68.2 million, according to December 2018 IQVIA data. Dr. Reddy's to acquire generic injectables portfolio Dr. Reddy's is set to 42 products with a market value of roughly $645 million. Zydus Cadila’s generic Xeljanz gets tentative approval Zydus Cadila's generic Xeljanz tablets are used to treat moderate to severe forms of rheumatoid arthritis. Sandoz resubmits Neulasta biosimilar application to FDA Sandoz's biosimilar of Neulasta, pegfilgrastim, is a long-acting version of filgrastim for cancer patients. FDA gives tentative nod to Zydus Cadila’s generic Vimpat Lacosamide is an anticonvulsant drug used to prevent and control seizures. Amneal appoints new chief scientific officer Pradeep Bhadauria has more than two decades of generic and specialty pharmaceutical experience. Lupin names independent director Christine Mundkur has held leadership roles at Impopharma, Sandoz, and Barr. First Previous 175 176 177 178 179 Next Last